Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study

Detalhes bibliográficos
Autor(a) principal: Dibi, Raquel Papandreus
Data de Publicação: 2020
Outros Autores: Zettler, Claudio Galleano, Vanin, Carla Maria de Martini, Ribeiro, Rafaela Vanin Pinto, Oliveira, Júlia Monteiro de, Kremer, Thaysa Guglieri, Borges, Josiane, Kato, Sérgio Kakuta
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: https://periodicosapm.emnuvens.com.br/spmj/article/view/572
Resumo: BACKGROUND: Endometrial polyps are common in postmenopausal women, and the effect of tamoxifen use (a risk factor for endometrial polyps) on their pathogenesis is unclear. OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. DESIGN AND SETTING: Cross-sectional analytical study in a tertiary-level academic hospital. METHODS: 46 women (14 tamoxifen users and 32 nonusers) with postmenopausal bleeding underwent hysteroscopic resection of endometrial polyps. Polyp samples were immunohistochemically assessed for detection of Ki-67, Bcl-2 and estrogen and progesterone receptors. RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). All polyps in nonusers and 92.3% of those in users were also positive for estrogen receptors (P = 0.295). Ki-67 was expressed in 75% of the polyps in the tamoxifen users and 82.8% of those in the nonusers. All endometrial polyps expressed Bcl-2. CONCLUSIONS: The immunohistochemical analysis on endometrial polyps demonstrated that, although tamoxifen is considered to be a risk factor for endometrial polyps, there were no significant differences in the expression of hormone receptors between users and nonusers of tamoxifen. There were no between-group differences in Ki-67 and Bcl-2 expression, and all patients displayed inhibition of apoptosis by Bcl-2, thus supporting the theory that polyps develop due to inhibition of apoptosis, and not through cell proliferation.
id APM-1_0e76b9fb9ce32463d1e7d85ab360890f
oai_identifier_str oai:ojs.diagnosticoetratamento.emnuvens.com.br:article/572
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control studyPolypsTamoxifenMenopauseImmunohistochemistryGynecologyEndometriumBACKGROUND: Endometrial polyps are common in postmenopausal women, and the effect of tamoxifen use (a risk factor for endometrial polyps) on their pathogenesis is unclear. OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. DESIGN AND SETTING: Cross-sectional analytical study in a tertiary-level academic hospital. METHODS: 46 women (14 tamoxifen users and 32 nonusers) with postmenopausal bleeding underwent hysteroscopic resection of endometrial polyps. Polyp samples were immunohistochemically assessed for detection of Ki-67, Bcl-2 and estrogen and progesterone receptors. RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). All polyps in nonusers and 92.3% of those in users were also positive for estrogen receptors (P = 0.295). Ki-67 was expressed in 75% of the polyps in the tamoxifen users and 82.8% of those in the nonusers. All endometrial polyps expressed Bcl-2. CONCLUSIONS: The immunohistochemical analysis on endometrial polyps demonstrated that, although tamoxifen is considered to be a risk factor for endometrial polyps, there were no significant differences in the expression of hormone receptors between users and nonusers of tamoxifen. There were no between-group differences in Ki-67 and Bcl-2 expression, and all patients displayed inhibition of apoptosis by Bcl-2, thus supporting the theory that polyps develop due to inhibition of apoptosis, and not through cell proliferation.São Paulo Medical JournalSão Paulo Medical Journal2020-02-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://periodicosapm.emnuvens.com.br/spmj/article/view/572São Paulo Medical Journal; Vol. 138 No. 1 (2020); 64-68São Paulo Medical Journal; v. 138 n. 1 (2020); 64-681806-9460reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APMenghttps://periodicosapm.emnuvens.com.br/spmj/article/view/572/516https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessDibi, Raquel PapandreusZettler, Claudio GalleanoVanin, Carla Maria de MartiniRibeiro, Rafaela Vanin PintoOliveira, Júlia Monteiro deKremer, Thaysa GuglieriBorges, JosianeKato, Sérgio Kakuta2023-07-26T17:43:43Zoai:ojs.diagnosticoetratamento.emnuvens.com.br:article/572Revistahttp://www.scielo.br/spmjPUBhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2023-07-26T17:43:43São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
title Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
spellingShingle Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
Dibi, Raquel Papandreus
Polyps
Tamoxifen
Menopause
Immunohistochemistry
Gynecology
Endometrium
title_short Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
title_full Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
title_fullStr Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
title_full_unstemmed Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
title_sort Immunohistochemical assessment of symptomatic postmenopausal endometrial polyps in tamoxifen users and nonusers: a case control study
author Dibi, Raquel Papandreus
author_facet Dibi, Raquel Papandreus
Zettler, Claudio Galleano
Vanin, Carla Maria de Martini
Ribeiro, Rafaela Vanin Pinto
Oliveira, Júlia Monteiro de
Kremer, Thaysa Guglieri
Borges, Josiane
Kato, Sérgio Kakuta
author_role author
author2 Zettler, Claudio Galleano
Vanin, Carla Maria de Martini
Ribeiro, Rafaela Vanin Pinto
Oliveira, Júlia Monteiro de
Kremer, Thaysa Guglieri
Borges, Josiane
Kato, Sérgio Kakuta
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dibi, Raquel Papandreus
Zettler, Claudio Galleano
Vanin, Carla Maria de Martini
Ribeiro, Rafaela Vanin Pinto
Oliveira, Júlia Monteiro de
Kremer, Thaysa Guglieri
Borges, Josiane
Kato, Sérgio Kakuta
dc.subject.por.fl_str_mv Polyps
Tamoxifen
Menopause
Immunohistochemistry
Gynecology
Endometrium
topic Polyps
Tamoxifen
Menopause
Immunohistochemistry
Gynecology
Endometrium
description BACKGROUND: Endometrial polyps are common in postmenopausal women, and the effect of tamoxifen use (a risk factor for endometrial polyps) on their pathogenesis is unclear. OBJECTIVES: To evaluate the expression of hormone receptors and markers for proliferation/apoptosis (Ki-67 and Bcl-2) in endometrial polyps in postmenopausal users and nonusers of tamoxifen. DESIGN AND SETTING: Cross-sectional analytical study in a tertiary-level academic hospital. METHODS: 46 women (14 tamoxifen users and 32 nonusers) with postmenopausal bleeding underwent hysteroscopic resection of endometrial polyps. Polyp samples were immunohistochemically assessed for detection of Ki-67, Bcl-2 and estrogen and progesterone receptors. RESULTS: Analysis on the glandular component of the polyps revealed progesterone receptor expression in the polyps of 96.9% of the nonusers of tamoxifen, and 92.3% of the tamoxifen users (P = 0.499). All polyps in nonusers and 92.3% of those in users were also positive for estrogen receptors (P = 0.295). Ki-67 was expressed in 75% of the polyps in the tamoxifen users and 82.8% of those in the nonusers. All endometrial polyps expressed Bcl-2. CONCLUSIONS: The immunohistochemical analysis on endometrial polyps demonstrated that, although tamoxifen is considered to be a risk factor for endometrial polyps, there were no significant differences in the expression of hormone receptors between users and nonusers of tamoxifen. There were no between-group differences in Ki-67 and Bcl-2 expression, and all patients displayed inhibition of apoptosis by Bcl-2, thus supporting the theory that polyps develop due to inhibition of apoptosis, and not through cell proliferation.
publishDate 2020
dc.date.none.fl_str_mv 2020-02-06
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicosapm.emnuvens.com.br/spmj/article/view/572
url https://periodicosapm.emnuvens.com.br/spmj/article/view/572
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://periodicosapm.emnuvens.com.br/spmj/article/view/572/516
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv São Paulo Medical Journal
São Paulo Medical Journal
publisher.none.fl_str_mv São Paulo Medical Journal
São Paulo Medical Journal
dc.source.none.fl_str_mv São Paulo Medical Journal; Vol. 138 No. 1 (2020); 64-68
São Paulo Medical Journal; v. 138 n. 1 (2020); 64-68
1806-9460
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1825135057209131008